The offering is dilutive with no disclosed total size, and the concurrent inducement agreement suggests existing warrant holders are being incentivized to exercise. Monitor the 6-K filing for the actual number of shares sold and the resulting dilution. The 60-day lock-up on further equity issuance provides a temporary floor but does not offset the immediate dilution.
Price Chart
Executive Summary
Scinai Immunotherapeutics entered into a securities purchase agreement on October 13, 2026, to sell ADSs and pre-funded warrants at $1.20 per ADS, along with Series A-1 warrants exercisable for 150% of the purchased ADSs at $1.20. The offering is dilutive to existing shareholders, and the company also entered into a warrant inducement agreement to exercise existing warrants concurrently. No total offering size or number of shares was disclosed in the filing.
Key Facts
- Securities Purchase Agreement dated October 13, 2026, for sale of ADSs and/or Pre-Funded Warrants at $1.20 per ADS.
- Purchasers receive Series A-1 Common Warrants exercisable for 150% of the number of ADSs purchased, at $1.20 per ADS.
- Pre-Funded Warrants have a nominal exercise price of $0.0001 per ADS.
- A concurrent Inducement Agreement was signed to induce exercise of existing warrants.
- Placement agent is A.G.P./Alliance Global Partners.
- Lock-up agreements from executive officers and directors are required.
- Company must file a resale registration statement within 15 calendar days of closing.
- 60-day restriction on further equity issuances and 180-day restriction on variable rate transactions after the effective date.
Financial Impact
Undisclosed total offering size; per ADS price of $1.20 with 150% warrant coverage creates significant potential dilution.
Risk Factors
- Significant dilution to existing shareholders from the new ADSs and warrants.
- Potential for further dilution if the Series A-1 warrants are exercised.
- No disclosed total offering size, creating uncertainty about the magnitude of dilution.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-109633 |
| Document: ea030860501ex10-2.htm | 0001213900-26-109633 |
| Document: ea030860501ex4-2.htm | 0001213900-26-109633 |
| Document: ea030860501ex4-1.htm | 0001213900-26-109633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers